INFLAZYME PHARMACEUTICALS EYES $5.9M GAIN FROM REORGANIZATION

Inflazyme Pharmaceuticals Ltd. expects to gain about $5.9 million from a reorganization and the sale of one of its subsidiaries. The restructuring initially provides $3.43 million to help fund Inflazyme operations. And the firm (TSX:IZP) said Wednesday it expects to receive an additional $2.5 million from selling its holding in the unnamed subsidiary before next March 15. Inflazyme Pharmaceuticals makes products used in treating respiratory and inflammatory diseases.

Canada.com (http://www.canada.com/businesscentre/story.html?id=9de37067-71ea-4def-8f0e-fe52c874d206)